Ziftomenib

Roswell Park's Dr. Eunice Wang led KOMET-001 trial of ziftomenib in AML patients, showing 33% response rate in those with prior therapies. The drug, a menin inhibitor, particularly benefited those with NPM1 mutations or KMT2A rearrangements, prompting FDA Breakthrough Therapy designation.

Kura Oncology appoints Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles brings over 25 years of oncology drug development experience and leadership. He is currently a Senior Advisor at Frazier Healthcare Partners and has held senior roles at ImmunoGen, Flatiron Health, Unum Therapeutics, Takeda/Millennium, and Genzyme Corporation. Dr. Vasconcelles expressed enthusiasm for Kura's precision oncology approach and its menin inhibitor program for acute leukemias.

Kura Oncology (KURA) is a clinical-stage biopharmaceutical company developing precision medicines for cancer, with key candidates like Tipifarnib, Ziftomenib, and KO-2806. Recent achievements include preliminary data from the KOMET-007 trial and securing financing through 2027.